Association Between Cardiovascular Risk and Perceived Fatigability in Mid-to-Late Life

Yujia Qiao, MBBS, BM; Pablo Martinez-Amezcua, MD, MHS; Amal A. Wanigatunga, PhD, MPH; Jacek K. Urbanek, PhD; Eleanor M. Simonsick, PhD; Luigi Ferrucci, MD, PhD; Jennifer A. Schrack, PhD

Background—Cardiovascular disease (CVD) and fatigue commonly co-occur in older adults, yet the subjective nature of fatigue and its situational dependence leave the true magnitude of this association undefined.

Methods and Results—Six-hundred and twenty-five participants with no history of CVD (aged 68.1±12.0 years), from the Baltimore Longitudinal Study of Aging who underwent ≥2 clinic visits between 2007 and 2015 were classified according to sex-specific predicted 10-year CVD risk scores using the Framingham CVD risk score (Framingham) and the Pooled Cohort Equation at baseline. Perceived fatigability was assessed using the Borg rating of perceived exertion scale after a 5-minute treadmill walk (0.67 m/s, 0% grade). Linear models were used to assess the association between baseline CVD risk and perceived fatigability an average of 4.5 years later, adjusted for demographics, behaviors, and medical history. In final models, a 5% higher baseline Pooled Cohort Equation score was associated with greater perceived fatigability at follow-up ($\beta$=0.13 rating of perceived exertion, $P=0.008$). Stratified analyses suggested this association was stronger among those aged ≤70 years and those with obesity. Of the individual CVD risk score components, older age was most strongly associated with perceived fatigability ($\beta$=0.48, $P<0.001$), followed by women ($\beta$=0.11, $P=0.002$), and treated hypertension ($\beta$=0.11, $P=0.003$). There was no association with the Framingham risk score.

Conclusions—Perceived fatigability was higher among participants with greater CVD risk measured using the Pooled Cohort Equation risk score. The strong associations with hypertension and obesity suggest prevention and promotion of cardiovascular health may also lower perceived fatigability, particularly among those aged ≤70 years or living with obesity. (J Am Heart Assoc. 2019;8:e013049. DOI: 10.1161/JAHA.119.013049.)

Key Words: cardiovascular disease risk factors • cardiovascular risk • fatigability • older adults

Cardiovascular disease (CVD) is the leading cause of the death worldwide with the number of CVD deaths expected to increase from an estimated 17.9 million in 2016 to >23.6 million by 2030.1,2 In 2015, the American Heart Association estimated that 85.6 million Americans had >1 type of CVD, and of these, 43.7 million (51.1%) were ≥60 years old.3 The onset and progression of elevated CVD risk is detrimental to quality of life and future health outcomes, particularly among older adults, often inducing activity limitations3 and fatigue,5 which further exacerbate the progression of CVD events. Efforts to prevent CVD and its associated health outcomes are thus paramount to preserving health and functional status in a rapidly aging population.

Fatigue is a common complaint among older adults and a prominent symptom among those with chronic cardiovascular conditions.6 Because of its subjective nature, the severity of fatigue is often difficult to quantify and define, as it is confounded by reductions in the amount and/or intensity of physical activity as older adults adjust their exertion levels to attenuate or avoid fatigue. In this context, people reporting a similar level of fatigue could differ dramatically in terms of physical capacity,7 thus potentially under-or-over-stating the true magnitude and intensity of the association between fatigue and cardiovascular conditions.

Fatigability is a relatively recent construct developed and validated in the gerontological literature to better understand the development and progression of fatigue, and associated changes with mobility and functional capacity with aging.8
Clinical Perspective

What Is New?

- Introduce the construct of fatigability, or fatigue in relationship to a standardized task, to scientists and clinicians working in cardiovascular disease research.
- Perceived fatigability was higher among those with greater cardiovascular disease risk at baseline.
- Strong associations were observed among those aged ≤70 years or living with obesity.

What Are the Clinical Implications?

- Perceived fatigability may provide an early, sensitive measure of functional status.
- Findings from our work to date reveal differential associations across indicators of health and disease.
- Future interventions to attenuate fatigability in older adults may focus on reducing cardiovascular disease burden.

Previous research has shown that those with preclinical peripheral artery disease, as indicated by low ankle brachial index, experience greater fatigability and lower walking endurance than those with normal ankle brachial index, suggesting that high fatigability may act as an early indicator of peripheral artery disease. Further, cardiovascular risk factors like arterial stiffness and diabetes mellitus have been positively associated with higher fatigue, yet the contribution of these risk factors to the development of fatigability has not been defined. Given that most CVD risk factors are modifiable, efforts to prevent the onset and progression of fatigability with aging may benefit from evaluation and management of cardiovascular health earlier in life. Moreover, high fatigability may also act as a symptom of preclinical CVD, assisting with earlier clinical diagnoses.

Accordingly, this study assesses the association between CVD risk and fatigability measured, on average, 4.5 years later in a population of well-functioning middle-aged and older adults with no history of CVD. In addition, we explored the independent associations between fatigability and factors most commonly associated with CVD risk (eg, hypertension, hypercholesterolemia, diabetes mellitus, etc). We hypothesized that people with higher CVD risk would have higher fatigability and that this would be primarily driven by hypertension, given its high prevalence among older adults.

Methods

Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to the Intramural Research Program of the National Institute on Aging at https://blsa.nih.gov.

Study Population

The Baltimore Longitudinal Study of Aging (BLSA) is a study of normative human aging, established in 1958 and conducted by the National Institute on Aging Intramural Research Program. A general description of the sample and enrollment criteria has been previously reported. Briefly, the BLSA is a continuously enrolled cohort with some targeted recruitment (women, racial minorities) over its history. All participants are community-dwelling volunteers who pass a comprehensive health and functional screening evaluation, and are free of major chronic conditions and cognitive and functional impairments at the time of enrollment. Once enrolled, participants are followed for life, regardless of disease development, and undergo extensive testing every 1 to 4 years depending on age. The eligible sample for the current study consists of 742 participants who underwent perceived fatigability and health history assessments at least twice between 2007 and 2015. Participants with missing data on baseline information including total cholesterol, high-density lipoprotein cholesterol, or smoking status (n=49) were excluded. Participants were also excluded if they had previously been diagnosed with CVD (n=68), resulting in a final sample of 625 participants. BLSA study protocol was approved by the National Institute for Environmental Health Sciences Internal Review Board and all participants provided written informed consent.

Predicted 10-Year CVD Risk

The exposure variable was sex-specific predicted 10-year CVD risk calculated using both the Framingham CVD risk score (Framingham) and Pooled Cohort Equation (PCE) when perceived fatigability was first measured, which serves as the baseline for this study. The adjudicated end points for these 2 risk scores are slightly different. For estimated absolute end points, the Framingham score indicates a broader composite of CVD events containing coronary heart disease, cerebrovascular events, peripheral artery disease, and heart failure, while the PCE score mainly covers hard cardiovascular events including coronary heart disease death, myocardial infarction, and fatal and non-fatal stroke. The risk scores indicate a probability of first developing any of the listed end points over a 10-year period. Both risk scores include variables for age, sex, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, antihypertension medication use, diabetes mellitus status, and current smoking status. Furthermore, self-identified black or non-black race is included only in the PCE score, which helps to differentiate the
Cardiovascular Risk and Perceived Fatigability

Qiao et al

DOI: 10.1161/JAHA.119.013049

Journal of the American Heart Association

‡

*Current alcohol drinker is defined as >1 drink/day. Smoking status was classified as current smokers versus past or never smokers. During the interview, participants were also asked to report whether they were ever told by a doctor or other health professional that they had any of the following conditions: diagnosed CVD including angina, myocardial infarction, congestive heart failure, peripheral artery disease, and vascular-related procedures (including coronary artery bypass grafting or angioplasty); hypertension or high blood pressure; diabetes mellitus; pulmonary disease, kidney disease, peripheral neuropathy, cancer, or lower extremity arthritis pain. Participants having diagnosed CVD at baseline were excluded. Except for hypertension and diabetes mellitus which were included in the CVD risk score calculations, the rest of the responses were summed and categorized into several chronic conditions (range 0–4). Current medication use was assessed as part of the in-person visit.

Height and weight were assessed in light clothing using a stadiometer and calibrated scale, respectively, and body mass index (BMI) was calculated as mass in kilograms divided by height in meters squared (kg/m²). Systolic blood pressure was measured 3 times in each arm using an automated testing device (Colin VP2000/1000), following standardized procedures.9 The average of these 3 trials on both arms (total 6 trials)

Table 1. Baseline Characteristics According to Fatigability Category among 625 Participants

| Characteristics          | Overall | RPE 6 to 7 | RPE 8 to 9 | RPE 10 to 11 | RPE ≥12 | P Trend (unadjusted) | P Trend (adjusted for age and sex) |
|--------------------------|---------|------------|------------|--------------|---------|----------------------|-----------------------------------|
| Age (y), mean±SD         | 68.08±12.04 | 62.85±11.58 | 70.32±10.47 | 73.12±10.50 | 76.72±9.23 | <0.001               | <0.001                            |
| Female, %                | 56.64   | 53.10      | 59.21      | 58.93        | 61.97    | 0.116                | 0.008                             |
| Black race, %            | 27.64   | 29.31      | 28.29      | 32.14        | 21.13    | 0.463                | 0.386                             |
| Current smoker, %        | 1.28    | 1.38       | 1.97       | 0.89         | 0        | 0.389                | 0.696                             |
| Current alcohol drinker*, % | 83.84  | 87.59      | 81.58      | 81.25        | 77.46    | 0.018                | 0.079                             |
| Total cholesterol (mg/dL), mean±SD | 192.5±34.5 | 192.5±35.1 | 192.5±34.4 | 191.6±34.6 | 194.8±32.7 | 0.786                | 0.853                             |
| HDL-C (mg/dL), mean±SD   | 60.8±16.7 | 59.8±16.6  | 61.8±17.1  | 62.6±14.9    | 60.3±18.2 | 0.316                | 0.297                             |
| SBP (mm Hg), mean±SD     | 114.7±13.4 | 112.9±13.0 | 116.8±13.8 | 115.0±12.9   | 117.4±14.5 | 0.007                | 0.234                             |
| DBP (mm Hg), mean±SD     | 64.8±8.5  | 65.5±8.4   | 65.1±8.3   | 64.7±8.2     | 61.5±8.9  | 0.002                | 0.997                             |
| BMI (kg/m²), mean±SD     | 26.7±4.5  | 26.2±4.2   | 26.9±4.8   | 27.0±4.6     | 27.8±4.9  | 0.005                | <0.001                            |
| Hypertension†, %         | 35.84   | 25.86      | 42.11      | 43.75        | 50.70    | <0.001               | 0.002                             |
| Diabetes‡, %             | 5.12    | 4.48       | 5.26       | 3.57         | 9.86     | 0.236                | 0.160                             |
| Have chronic disease§, % | 44.00   | 34.48      | 52.63      | 49.11        | 56.34    | <0.001               | 0.060                             |
| Framingham score         | 12.65±10.10 | 10.41±9.03 | 13.79±9.86 | 13.70±9.44   | 17.67±13.05 | <0.001               | 0.014                             |
| PCE score                | 15.47±14.48 | 10.12±10.94 | 17.15±14.15 | 20.28±15.52 | 26.14±16.84 | <0.001               | 0.004                             |

BMI indicates body mass index; DBP, diastolic blood pressure; Framingham, Framingham CVD risk score; HDL-C, high-density lipoprotein cholesterol; PCE, Pooled Cohort Equation; RPE, Rating of Perceived Exertion after a slow-paced 5 min treadmill walk; SBP, systolic blood pressure; SD, standard deviation.

*Current alcohol drinker is defined as >1 drink/day.
†Hypertension is defined by SBP ≥140 mm Hg or DBP ≥90 mm Hg or treatment with antihypertensive drugs.
‡Diabetes is defined by fasting blood glucose ≥126 mg/dL or treatment with hypoglycemic drugs.
§Chronic diseases include history of: pulmonary disease, kidney disease, neuropathy, cancer, lower extremity arthritis pain.
was used for analysis. Total cholesterol, high-density lipoprotein cholesterol, and fasting glucose were measured using blood samples collected between 7 and 8 AM after an overnight fast (from the prior night starting at 10 PM). Participants were not permitted to smoke, engage in physical activity, or take medications before the blood sample collection. The concentration of total cholesterol was measured by an enzymatic method (Abbott Laboratories ABA-200 ATC Biochromatic Analyzer, Irving, TX). The concentration of high-density lipoprotein cholesterol was evaluated by a dextran sulfate-magnesium precipitation procedure. The fasting plasma glucose concentration was determined by the glucose oxidase method (Beckman Instruments, Inc., Fullerton, CA).

Statistical Analysis

To characterize the population (N=625), participants were classified into 4 groups based on their RPE at their most recent visit, and baseline characteristics were reported as mean±SD or frequencies (proportions). Tests for linear trend were conducted to detect mean differences among groups (Table 1) using t test.

In preliminary analyses, univariate linear regression models were conducted to estimate the continuous crude regression coefficients (β) and 95% CIs for the associations between baseline 10-year predicted CVD risk and most recent measure of perceived fatigability. Subsequently, multivariable models were conducted to account for established and potential confounders using progressive covariate adjustment (Table 2). Model 1 was adjusted for age, sex, and time since baseline. Model 2 was additionally adjusted for BMI, and Model 3 further adjusted for several chronic diseases, and alcohol intake. Because of strict application of the CVD risk scores and potential confounding by medication use, sensitivity analyses were performed to assess the robustness of our results by: (1) excluding participants with subsequent CVD events (n=29), (2) excluding participants using statins (n=21), (3) stratifying by use of beta-blockers, and (4) stratifying by use of anti-hypertension medications among hypertensive participants (n=308).

To assess whether the burden of 10-year predicted CVD risk on perceived fatigability was differential by age or BMI, stratified analyses were also performed. Participants were dichotomized at age 70 and an interaction term between the dichotomous age variable and continuous RPE was added to the Model 3 (Figure). In a separate model, participants were also dichotomized at BMI ≥30 kg/m² and an interaction term between dichotomous BMI and continuous RPE was explored. Finally, to explore the burden of the individual contributions of the components of the 10-year predicted CVD risk scores on fatigability, each component was modeled independently and standardized βs were estimated from linear regression models adjusted for age, sex, time since baseline, and self-identified race (Table 3). All analyses were performed using STATA version 14 (Statacorp, College Station, TX), and 2-sided P-values <0.05 were considered significant.

Results

Baseline Characteristics of Population

Of the 625 participants aged 32 to 95 years at baseline (mean±SD: 68.1±12.0) included in the analysis, 354 (56.6%) were women, and 179 (27.6%) were of black race. The mean follow-up time was 4.5±1.8 years. The predicted Framingham score among all participants was 12.7±10.1, and the PCE score was 15.5±14.5. The mean perceived fatigability (RPE) for the population was 8.6±2.4. Those with higher RPE were more likely to be older, have a higher BMI, and to have hypertension, and other non-cardiovascular chronic conditions, and they were less likely to consume alcohol on a regular basis. Moreover, there was a trend towards higher Framingham and PCE scores among those in the higher RPE categories (unadjusted P-trend<0.001) (Table 1).

Association Between Predicted 10-Year CVD Risk and Perceived Fatigability

On a continuous scale, perceived fatigability was higher among participants with higher predicted 10-year CVD risk as

Table 2. Continuous Association Between 10-Year CVD Risk Score and Perceived Fatigability (Borg RPE) (N=625)

| Predictor       | 5% Higher Framingham Score | 5% Higher PCE Score |
|-----------------|-----------------------------|---------------------|
|                 | β Coefficient (95% CI) | P Value | β Coefficient (95% CI) | P Value |
| Crude model     | 0.27 (0.18, 0.36) | <0.001 | 0.33 (0.27, 0.39) | <0.001 |
| Model 1         | 0.15 (0.03, 0.28) | 0.018 | 0.15 (0.06, 0.25) | 0.002 |
| Model 2         | 0.07 (−0.06, 0.20) | 0.283 | 0.14 (0.04, 0.24) | 0.006 |
| Model 3         | 0.05 (−0.08, 0.19) | 0.408 | 0.13 (0.04, 0.23) | 0.008 |

Model 1 adjusted for age, sex, and time since baseline. Model 2 adjusted for Model 1 + BMI (kg/m²). Model 3 adjusted for Model 2 + number of chronic diseases (ranging from 0 to 4), and alcohol intake (current drinkers, abstainers). BMI indicates body mass index; Framingham score, Framingham CVD risk score; PCE, Pooled Cohort Equation; RPE, Rating of Perceived Exertion after a slow-paced 5 min treadmill walk.
measured using the Framingham and the PCE scores. Each 5% higher Framingham risk score corresponded to a 0.27 higher perceived fatigability as measured by RPE \((P<0.001)\), and each 5% higher in the PCE score corresponded to a 0.33 higher in RPE \((P<0.001)\). These associations were attenuated after adjusting for age, sex, and time since baseline, (Table 2, Model 1) but remained significant. After further adjusting for BMI, only the association with the PCE score remained \((\beta=0.14 \text{ RPE}, P=0.006)\) (Table 2, Model 2). In the final model which also included several chronic diseases and reported alcohol intake, the association with the PCE score remained essentially unchanged \((\beta=0.13 \text{ RPE}, P=0.008)\) (Table 2, Model 3).

Sensitivity analyses revealed these results to be robust. To minimize the influence of CVD events on perceived fatigability, participants with a subsequent CVD diagnosis \((n=29)\) were excluded from the final model. The results remained essentially unchanged: each 5% higher Framingham score corresponded to 0.10 higher RPE \((P=0.151)\) and each 5% higher PCE score corresponded to a 0.14 higher RPE \((P=0.005)\) (Table S1). To assess the potential effects of medication use, participants using statins \((n=21)\) were excluded since the derivation cohort for PCE risk score was free of statin use; the results remained essentially unchanged (Table S2). Further analyses to assess the effects of beta-blockers and antihypertensive medications, on RPE did not reveal any significant findings (Tables S3 and S4).

Table 3. Associations Between Each CVD Risk Score Components and Perceived Fatigability

|                     | Standardize \(\beta\) Coefficient* | \(P\) Value | Fully Adjusted Standardize \(\beta\) Coefficient† \(P\) Value |
|---------------------|------------------------------------|-------------|-------------------------------------------------------------|
| Age, y              | 0.461                              | <0.001      | 0.481 <0.001                                                |
| Female              | 0.118                              | 0.001       | 0.112 0.002                                                 |
| Black               | 0.075                              | 0.038       | 0.063 0.082                                                 |
| Total cholesterol, mg/dL | 0.033                     | 0.355       | 0.003 0.292                                                 |
| HDL-C, mg/dL        | 0.009                              | 0.808       | –0.040 0.227                                                |
| SBP, mm Hg          | 0.028                              | 0.442       | 0.039 0.289                                                 |
| Anti-hypertension medication | 0.116                      | 0.002       | 0.109 0.003                                                 |
| Diabetes            | 0.035                              | 0.333       | 0.037 0.296                                                 |

HDL-C indicates high-density lipoprotein cholesterol; SBP, systolic blood pressure.
*Adjusted for age and time since baseline.
†Adjusted for age, sex, back/non-black and time since baseline.

Stratified Analysis

In age-stratified analyses, the positive association between predicted CVD risk and RPE tended to be higher among participants ≤70 years across both risk scores but PCE score did not reach significance \((\beta=0.25 \text{ RPE} (P_{interaction}=0.152)\) for Framingham score; \(\beta=0.32 \text{ RPE} (P_{interaction}=0.172)\) for PCE score), with null effects among those aged >70. In BMI-stratified analyses, the combined effects of predicted CVD risk and obesity trended toward being larger among obese participants (BMI ≥30 kg/m\(^2\)) than non-obese participants for both risk scores \((\beta=0.33 \text{ RPE} (P_{interaction}=0.660)\) for Framingham score; \(\beta=0.38 \text{ RPE} (P_{interaction}=0.594)\) for PCE score) (Figure).

Association Between Each Component and Perceived Fatigability

To better understand the association between individual components of CVD risk and perceived fatigability, each
component of the risk score was evaluated independently, accounting for age, sex and race (Table 3). Older age was most strongly associated with higher perceived fatigability (standardized β=0.48, P<0.001), followed by women (standardized β=0.11, P=0.002). Of the remaining CVD risk factors, the presence of hypertension was most strongly associated with higher perceived fatigability (standardized β=0.11, P=0.003), followed by black race (standardized β=0.06, P=0.082) (Table 3).

Discussion

Our results show that higher baseline CVD risk is associated with higher perceived fatigability an average of 4.5 years later, and that among modifiable CVD risk factors, treated hypertension was most strongly associated with higher perceived fatigability. Given the temporality, these findings illustrate the evolution of the association between CVD risk and perceived fatigability in a cohort of well-functioning older adults who are free of CVD events, and suggest that CVD risk, particularly hypertension, may be an important factor in the development and progression of fatigability in older adults. Previous studies exploring the burden of fatigue among those with CVD have consistently found a positive association between high fatigue and history of CVD events, particularly stroke, but the true burden of fatigue is difficult to discern because of its subjectivity. The current work expands on this research by anchoring fatigue to a standardized physical task and demonstrating a direct link between CVD risk and fatigability among CVD-free older adults.

In the current study, the PCE score demonstrated greater discriminatory power to detect the association between CVD risk and fatigability than the Framingham score. This may be because non-black participants demonstrated poorer CVD risk profiles in our population, which was not detected by the Framingham score since it did not include race. Further, our findings that the association between CVD risk and fatigability is stronger among those aged ≤70 years compared with those >70 years may indicate that elevated cardiovascular risk in early-to-mid-life is more deleterious in the development of fatigability compared with later-stage risk. To this end, corresponding interventions to promote cardiovascular health may be most beneficial when implemented in middle-, or even younger-age. Stronger associations between CVD risk and fatigability were also seen among those who are obese. This is consistent with recent findings, suggesting that higher BMI and central adiposity are strongly associated with physical fatigability in older adults. Although there is currently no clinical threshold for using RPE scores to assess fatigability, to put these results in some context we compared the RPE score for CVD burden with the beta coefficients for age from the same regression models. The difference in RPE score corresponding to a 5% higher PCE risk score (0.14 RPE score) was equivalent to nearly 2 years of age, suggesting that relatively small increments in RPE are equivalent to substantial differences in age.

Previous research has established an association between chronic fatigue and hypotension, but the association with hypertension has been less studied. Recently, studies focusing on patients with stroke and transient ischemic attack, reported that hypertensive subjects showed higher odds of being fatigued compared with their normotensive counterparts; however, the cause of the association between hypertension and fatigue remains unclear. Although the potential fatiguing effects of many antihypertension medications, including beta-blockers, has been postulated, our sensitivity analysis did not support this mechanism. Similarly, fatigue is also a persistent symptom among patients with diabetes mellitus, which is believed to be alleviated through improved glycemic control. Our study also indicated that the burden of fatigability is greater among women and those of black race, which are consistent with findings from previous studies on fatigue and health inequities.

The mechanisms contributing to higher fatigability among those with higher CVD risk remain to be explored. CVD risk places extra burden on multiple physiologic systems, including the coronary, pulmonary and vascular systems, which may contribute to increased perception of exertion or fatigue after a physical task because of hypoxemia and intermittent claudication. Other possible explanations include high inflammatory burden, immunity dysfunction and sleep disruptions that occur with CVD progression. Previous studies have demonstrated higher inflammatory burden among those with CVD, which may be a direct contributor to higher fatigability. Similarly, immunity cells such as B-cells, T Lymphocytes, and unconventional T cells, are more active among those with CVD, and produce more inflammatory factors under hypertensive conditions. Finally, sleep duration and quality are often impaired among those with hypertension and sleep apnea. Together, these mechanisms may contribute to long-term physiological stress, manifesting as high fatigability and eventual poor physical performance.

There are some limitations in the current study that should be considered. First, the BLSA participants are relatively healthy compared with the general older adult population, thus the magnitude of the results is likely understated compared with clinical populations. However, the strength of these results suggests that interventions to reduce CVD risk even in early-to-mid-life among well-functioning populations may be an effective strategy for reducing fatigability with aging. Future studies in sicker, more clinical populations are warranted. Second, there are missing data because of loss to
follow-up. Exploratory analyses indicated that the RPE scores are comparable between participants with and without missing data, thus it is unlikely that loss to follow-up altered the results. Some strengths should also be acknowledged. Objective measurement of perceived fatigability attenuates variability in subjective reporting, increasing the sensitivity and thus reducing the potential for misclassification. Further, the extensive data available on CVD risk enabled us to examine the independent and combine effects of CVD burden in the development of fatigability.

Conclusion
In conclusion, higher baseline CVD risk is associated with higher levels of perceived fatigability an average of 4.5 years later among well-functioning older adults free of CVD. Our findings provide researchers and clinicians new insights into the prevention and management of fatigability, enhancing understanding of the etiology of fatigability with aging and its association with CVD risk factors. Further studies are needed to confirm this association in clinical populations and to evaluate potential interventions to alleviate fatigability through effective evaluation and management of cardiovascular health.

Author Contributions
Qiao and Schrack contributed to the literature search, study design, data interpretation, statistical analyses, and writing and editing of the manuscript. All other co-authors contributed to the study design, data interpretation, and editing of the manuscript.

Sources of Funding
This work was supported in part by the Intramural Research Program of the National Institute on Aging, Maryland. Extramural funding provided by National Institutes of Health/National Cancer Institute R21 AG053198 and National Institutes of Health/National Institute on Aging P30AG021334.

Disclosures
None.

References
1. World Health Organization. Noncommunicable diseases country profiles 2018. 2018.
2. World Health Organization. Global status report on noncommunicable disease 2010. 2011.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kannel WB, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniyar L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JL, Woo D, Yeh RW, Turner MB. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322.
4. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, Kelly-Hayes M, Wolf PA, Kreger BE, Kannell WB. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994;84:351–358.
5. Eckhardt AL, Devin HA, Piano MR, Ryan CJ, Zerwic JJ. Fatigue in the presence of coronary heart disease. Nurs Res. 2014;63:83–93.
6. Avlund K. Fatigue in older adults: an early indicator of the aging process? Aging Clin Exp Res. 2010;22:100–115.
7. Simonsick EM, Schrack JA, Glynn NW, Ferrucci L. Assessing fatigability in mobility-intact older adults. J Am Geriatr Soc. 2014;62:347–351.
8. Eldadah BA. Fatigue and fatigability in older adults. PM R. 2010;2:406–413.
9. Martinez-Amezcua P, Matsushita K, Simonsick EM, Ferrucci L, Schrack JA. Fatigability and functional performance among older adults with low-normal ankle-brachial index: cross-sectional findings from the Baltimore Longitudinal Study of Aging. Atherosclerosis. 2018;272:200–206.
10. Gonzales JU, Wierg M, Defferari E, Proctor DN. Arterial stiffness is higher in older adults with increased perceived fatigue and fatigability during walking. Exp Gerontol. 2015;61:92–97.
11. Orlando G, Balducci S, Bazzucchi I, Pugliese G, Sacchetti M. The impact of type 2 diabetes and diabetic polyneuropathy on muscle strength and fatigability. Acta Diabetol. 2017;54:543–550.
12. Stone JL, Norris AH. Activities and attitudes of participants in the Baltimore Longitudinal Study. J Gerontol. 1964;21:575–580.
13. Agostino RB Sr, Vasan RS, Pencina MJ, Wang P, Cobain M, Massaro JM, Kannell WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753.
14. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Winkel J, Anderson JL, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Selike FW, Shen WK, Smith SC Jr, Tomasselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guide. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49–S73.
15. Robertson RJ, Noble BJ. Perception of physical exertion: methods, mediators, and applications. Exerc Sport Sci Rev. 1997;25:407–452.
16. Wannick GR, Bouter LM, Heine RJ. Symptoms and well-being in relation to glycemic control in type II diabetes. Atherosclerosis. 2010;210:93–108.
17. Sembra RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens. 2000;13:72–79.
18. Cuminb TB, Packter M, Kramer SF, English C. The prevalence of fatigue after stroke: a systematic review and meta-analysis. Int J Stroke. 2016;11:968–977.
19. Cooper R, Popham M, Santanasto AJ, Hardy R, Glynn NW, Kuh D. Are BMI and inflammatory markers independently associated with physical fatigue in old age? Int J Obes (Lond). 2019;43:832–841.
20. Martinez-Amezcua P, Simonsick EM, Wanigatunga AA, Urbanek JK, Shaffer NC, Ferrucci L, Schrack JA. The association between adiposity and physical fatigability in mid to late life. Obesity (Silver Spring). 2019;27:1177–1183. [Epub ahead of print].
21. Wessely S, Nickson J, Cox B. Symptoms of low blood pressure: a population study. BMJ. 1990;301:362–365.
22. Harbison JA, Walsh S, Kenny RA. Hypertension and daytime hypotension found on ambulatory blood pressure is associated with fatigue following stroke and TIA. QJM. 2009;102:109–115.
23. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–357.
24. Van der Does FE, De Neeling JN, Snoek FJ, Kostense PJ, Grootenhuis PA, Bouter LM, Heine RJ. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care. 1996;19:204–210.
25. Engberg I, Segerstedt J, Waller G, Wennberg P, Eliasson M. Fatigue in the general population- associations to age, sex, socioeconomic status, physical
activity, sitting time and self-rated health: the northern Sweden MONICA study 2014. *BMC Public Health*. 2017;17:654.

26. de Rekeneire N, Leo-Summers L, Han L, Gill TM. Epidemiology of restricting fatigue in older adults: the precipitating events project. *J Am Geriatr Soc*. 2014;62:476–481.

27. Meng H, Hale L, Friedberg F. Prevalence and predictors of fatigue in middle-aged and older adults: evidence from the Health and Retirement Study. *J Am Geriatr Soc*. 2010;58:2033–2034.

28. Wanigatunga AA, Varadhan R, Simonsick EM, Carlson OD, Studenski S, Ferrucci L, Schrack JA. Longitudinal relationship between interleukin-6 and perceived fatigability among well-functioning adults in mid-to-late life. *J Gerontol A Biol Sci Med Sci*. 2018;74:720–725.

29. Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. *Hypertension*. 2017;70:660–667.

30. Agita A, Alsagaff MT. Inflammation, immunity, and hypertension. *Acta Med Indones*. 2017;49:158–165.

31. Caillon A, Schiffrin EL. Role of inflammation and immunity in hypertension: recent epidemiological, laboratory, and clinical evidence. *Curr Hypertens Rep*. 2016;18:21.

32. Gangwisch JE. A review of evidence for the link between sleep duration and hypertension. *Am J Hypertens*. 2014;27:1235–1242.

33. Wanigatunga AA, Simonsick EM, Zipunnikov V, Spira AP, Studenski S, Ferrucci L, Schrack JA. Perceived fatigability and objective physical activity in mid- to late-life. *J Gerontol A Biol Sci Med Sci*. 2018;73:630–635.
SUPPLEMENTAL MATERIAL
Table S1. Sensitivity Analyses of Association between CVD Risk Score and Perceived Fatigability (Borg RPE), Excluding Those with Subsequent Diagnosed CVD (N=596).

|                      | 5% higher Framingham score |                      | 5% higher PCE score |
|----------------------|-----------------------------|----------------------|---------------------|
|                      | β coefficient (95% CI)      | p-value              | β coefficient (95% CI) | p-value |
| Crude Model          | 0.28 (0.19, 0.38)           | <0.001               | 0.33 (0.27, 0.39)    | <0.001  |
| Model 1              | 0.19 (0.06, 0.33)           | 0.003                | 0.17 (0.07, 0.27)    | 0.001   |
| Model 2              | 0.11 (-0.02, 0.25)          | 0.097                | 0.15 (0.05, 0.25)    | 0.003   |
| Model 3              | 0.10 (-0.04, 0.23)          | 0.151                | 0.14 (0.04, 0.24)    | 0.005   |

RPE = Rating of Perceived Exertion after a slow-paced 5 minutes treadmill walk; CVD = cardiovascular disease; Framingham risk score = Framingham CVD risk score; PCE = Pooled Cohort Equation; BMI = body mass index.

Model 1 adjusted for age, sex and time since baseline.

Model 2 adjusted for Model 1+ BMI (kg/m²).

Model 3 adjusted for Model 2 + number of chronic diseases (ranging from 0-4), and alcohol intake (current drinkers, abstainers).
Table S2. Sensitivity Analyses for Association Between CVD Risk Score and Perceived Fatigability (Borg RPE), excluding Participants Using Statins (N=604).

| Predictor      | 5% higher Framingham score | 5% higher PCE score |
|----------------|----------------------------|---------------------|
|                | β coefficient (95% CI)     | p-value             | β coefficient (95% CI) | p-value |
| Crude Model    | 0.27 (0.17, 0.36)          | <0.001              | 0.33 (0.27, 0.38)      | <0.001  |
| Model 1        | 0.16 (0.03, 0.29)          | 0.019               | 0.15 (0.05, 0.25)      | 0.003   |
| Model 2        | 0.07 (-0.06, 0.20)         | 0.308               | 0.13 (0.04, 0.23)      | 0.008   |
| Model 3        | 0.05 (-0.08, 0.18)         | 0.459               | 0.13 (0.03, 0.23)      | 0.011   |

RPE = Rating of Perceived Exertion after a slow-paced 5 minutes treadmill walk; Framingham risk score = Framingham CVD risk score; PCE = Pooled Cohort Equation; BMI = body mass index.

Model 1 adjusted for age, sex, and time since baseline.

Model 2 adjusted for Model 1+ BMI (kg/m²).

Model 3 adjusted for Model 2 + number of chronic diseases (ranging from 0-4), and alcohol intake (current drinkers, abstainers).
Table S3. Stratified Analyses of Association between CVD Risk Score and Perceived Fatigability (Borg RPE) among Beta-blocker Users (N=625).

|                          | 5% higher Framingham score | 5% higher PCE score |
|--------------------------|-----------------------------|---------------------|
|                          | β coefficient (95% CI)      | p-value             | β coefficient (95% CI) | p-value             |
|                          |                             |                     |                      |                     |
| Beta-blocker use (N=85)  | 0.14 (-0.20, 0.47)          | 0.423               | -0.07 (-0.35,0.20)   | 0.586               |
| No beta-blocker use (N=540) | 0.04 (-0.11,0.18)          | 0.610               | 0.18 (0.07,0.29)     | 0.002               |

RPE = Rating of Perceived Exertion after a slow-paced 5 minutes treadmill walk; CVD = cardiovascular disease; Framingham risk score = Framingham CVD risk score; PCE = Pooled Cohort Equation; BMI = body mass index.

Model adjusted for age, sex, BMI (kg/m²), time since baseline, number of chronic disease (ranging from 0-4), and alcohol intake (current drinkers, non-current drinkers).
|                          | 5% higher Framingham score | 5% higher PCE score |
|--------------------------|---------------------------|---------------------|
|                          | β coefficient (95% CI)    | p-value             | β coefficient (95% CI)    | p-value             |
|                          |                           |                     |                           |                     |
| Anti-hypertension medicine | -0.03 (-0.22, 0.16)       | 0.775               | 0.03 (-0.14, 0.20)        | 0.764               |
| (N=224)                  |                           |                     |                           |                     |
| No anti-hypertension medication | 0.14 (-0.32, 0.60)       | 0.551               | 0.02 (-0.25, 0.29)        | 0.882               |
| (N=84)                  |                           |                     |                           |                     |

RPE = Rating of Perceived Exertion after a slow-paced 5 minutes treadmill walk; CVD = cardiovascular disease; Framingham risk score = Framingham CVD risk score; PCE = Pooled Cohort Equation; BMI = body mass index.

Model adjusted for age, sex, BMI (kg/m²), time since baseline, number of chronic disease (ranging from 0-4), and alcohol intake (current drinkers, non-current drinkers).